
GIPL does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for GIPL and 80,000+ other tickers.
See exactly how GIPL's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for GIPL and 80,000+ other tickers.
Global Innovative Platforms Inc. engages in the business of testing breath to detect and assist in the treatment of disease. The company develops Heartworm breath test, which includes breath collection device, to collect shallow breath samples. It also operates VOCAM Plus and FROG platform for gas chromatography, as well as operates A.I. software to provide breath and air analysis. The company was formerly known as Canning Str Corp. and changed its name to Global Innovative Platforms Inc. in September 2021. Global Innovative Platforms Inc. was incorporated in 2020 and is based in Sanford, Florida.
No recent news available.